iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Sofosbuvir/Velpatasvir
 
 
  Sofosbuvir/velpatasvir - (06/07/16)
 
--------------------------------
 
UNRESTRICTED MEDICAID ACCESS TO NOVEL HEPATITIS C THERAPIES MAY REDUCE OVERALL COSTS, IMPROVE OUTCOMES - (06/29/16)
 
---------------------------------
 
FDA approved Sof/velpatasvir June 28 2016
 
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
 
EASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)
 
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)
 
EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
 
---------------------------------
 
U.S. Food and Drug Administration Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C - (06/29/16)
 
FDA approves Epclusa for treatment of chronic Hepatitis C virus infection - (06/29/16)
 
Sofosbuvir/Valpatasvir FDA Product Label - (06/29/16)
 
  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org